This large-scale retrospective study was conducted to evaluate the effectiveness and safety of eribulin for the treatment of metastatic breast cancer in real-world settings in Korea.
Patients who received eribulin between Jun 2014 and December 2016 at 14 hospitals in Korea for treatment of locally advanced or metastatic breast cancer were analyzed in this study. The Primary endpoint was progression-free survival(PFS) rate at 6 months. The Secondary endpoints included PFS, overall survival (OS), time to treatment failure(TTF), overall response rate (ORR) and hematologic adverse events.
In total, 398 patients’ medical records have been collected and were included in safety analysis set(SAS). Median age was 53 years old and the median number of previous chemotherapy regimens for advanced disease was 3 (range, 0-14). A median of 5 cycles of eribulin (range, 1-34) were administered. Among SAS, 360 patients’ records were included in full analysis set(FAS) and have been analyzed for the evaluation of efficacy. The PFS rate at 6 months was 37.78% and the median PFS, OS and TTF was 134, 631, and 120 days, respectively. The best overall response was confirmed as complete response (CR) 0.83%(3/360), partial response (PR) 17.22% (62/360), stable disease (SD) 31.39%(113/360) and progression disease (PD) 50.56%(182/360). We were able to collect only hematologic adverse events and in total, 65.08%(259/398) hematologic adverse events have been reported. The most frequent treatment-emergent adverse events were neutropenia (56.8%) and Anemia (11.3%).
The efficacy and safety of eribulin in Korea, in a real world setting, was consistent with previous Asian studies, with no other notable hematologic adverse events observed.
NCT03437083.
Eisai Korea Company.
Eisai Korea Company.
All authors have declared no conflicts of interest.